Literature DB >> 25787185

On the origin of EDSS.

John F Kurtzke1.   

Abstract

The origin of EDSS, the Expanded Disability Status Scale for multiple sclerosis, was some 30 years before its only publication in 1983 when we were trying to assess a potential treatment and found no published methods. Findings from the complete neurologic examinations in over 200 patients were consolidated into mutually exclusive but all-inclusive neurophysiologic entities called Functional Systems (FS), and these provided the basis for an 11 step 0-10 rank order scale, the Disability Status Scale (DSS). This was used successfully, as well as in the first two Class I treatment trials performed, with the second one also incorporating the 8 FS. Both measures were part of an assessment of a natural history series derived from men hospitalized for MS in the US Army in World War II and followed for some 20 years. Describing each of the 8 FS as affected (1) or normal (0) defined 256 possible patterns of involvement for all patients. Half the patients at diagnosis had one of the 14 most common patterns. Each FS worsened in frequency and severity of involvement in correlation with the DSS, which overall showed a unimodal distribution, until in another series of patients 16 years post onset bimodality first appeared. Observations that the 11 step DSS might have too few steps for treatment trials led to the EDSS of 20 steps with each grade between 1 and 9 divided into two. The system of EDSS+FS to summarize all the CNS involvement as defined by objective findings on neurologic examination thereafter remained unchanged to the present. I just learned that the unpublished system copyrighted in Switzerland as "neurostatus" has been called and referenced as my EDSS. It is not.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DSS; Disability measurement; EDSS; Functional systems (FS); MS; Treatment trials

Mesh:

Year:  2015        PMID: 25787185     DOI: 10.1016/j.msard.2015.02.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  18 in total

1.  Pelvic floor muscle training adapted for urinary incontinence in multiple sclerosis: a randomized clinical trial.

Authors:  Denise Cuevas Pérez; Carolina Walker Chao; Lucía Llanos Jiménez; Ignacio Mahíllo Fernández; Ana Isabel de la Llave Rincón
Journal:  Int Urogynecol J       Date:  2019-06-10       Impact factor: 2.894

Review 2.  Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.

Authors:  Carol Chase Huizar; Itay Raphael; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2020-09-20       Impact factor: 4.868

3.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Robin Conwit; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robert T Naismith; Akshata Ashokkumar; Janel Barnes; Dixie Ecklund; Elizabeth Klingner; Maxine Koepp; Jeffrey D Long; Sneha Natarajan; Brenda Thornell; Jon Yankey; Robert A Bermel; Josef P Debbins; Xuemei Huang; Patricia Jagodnik; Mark J Lowe; Kunio Nakamura; Sridar Narayanan; Ken E Sakaie; Bhaskar Thoomukuntla; Xiaopeng Zhou; Stephen Krieger; Enrique Alvarez; Michelle Apperson; Khurram Bashir; Bruce A Cohen; Patricia K Coyle; Silvia Delgado; L Dana Dewitt; Angela Flores; Barbara S Giesser; Myla D Goldman; Burk Jubelt; Neil Lava; Sharon G Lynch; Harold Moses; Daniel Ontaneda; Jai S Perumal; Michael Racke; Pavle Repovic; Claire S Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Guttman; Vijayshree Yadav; Aram Zabeti
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

4.  Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.

Authors:  Keren Regev; Brian C Healy; Fariha Khalid; Anu Paul; Renxin Chu; Shahamat Tauhid; Subhash Tummala; Camilo Diaz-Cruz; Radhika Raheja; Maria A Mazzola; Felipe von Glehn; Pia Kivisakk; Sheena L Dupuy; Gloria Kim; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi; Rohit Bakshi
Journal:  JAMA Neurol       Date:  2017-03-01       Impact factor: 18.302

5.  Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis.

Authors:  W Brola; P Sobolewski; W Szczuchniak; A Góral; M Fudala; W Przybylski; J Opara
Journal:  Eur J Clin Nutr       Date:  2016-03-30       Impact factor: 4.016

6.  7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis: How Does Spatial Resolution Affect the Detectability of Metabolic Changes in Brain Lesions?

Authors:  Eva Heckova; Bernhard Strasser; Gilbert J Hangel; Michal Považan; Assunta Dal-Bianco; Paulus S Rommer; Petr Bednarik; Stephan Gruber; Fritz Leutmezer; Hans Lassmann; Siegfried Trattnig; Wolfgang Bogner
Journal:  Invest Radiol       Date:  2019-04       Impact factor: 6.016

Review 7.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

8.  Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients.

Authors:  Marco Iannetta; Maria Antonella Zingaropoli; Tiziana Latronico; Ilaria Pati; Simona Pontecorvo; Carla Prezioso; Valeria Pietropaolo; Antonio Cortese; Marco Frontoni; Claudia D'Agostino; Ada Francia; Vincenzo Vullo; Claudio Maria Mastroianni; Grazia Maria Liuzzi; Maria Rosa Ciardi
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

9.  Treating Post-traumatic Stress Disorder in Patients with Multiple Sclerosis: A Randomized Controlled Trial Comparing the Efficacy of Eye Movement Desensitization and Reprocessing and Relaxation Therapy.

Authors:  Sara Carletto; Martina Borghi; Gabriella Bertino; Francesco Oliva; Marco Cavallo; Arne Hofmann; Alessandro Zennaro; Simona Malucchi; Luca Ostacoli
Journal:  Front Psychol       Date:  2016-04-21

10.  Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Authors:  João J Cerqueira; D Alastair S Compston; Ruth Geraldes; Mario M Rosa; Klaus Schmierer; Alan Thompson; Michela Tinelli; Jacqueline Palace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-04-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.